We are delighted to announce the promotion of Josh DeClercq to principal biostatistician, in effect as of May 1. A 2018 graduate of our department's MS program, DeClercq previously earned his bachelor's degree in genetics at the University of California, Davis, and worked at Siemens Healthcare Diagnostics, New York University School of Medicine, and Sangamo Biosciences before moving to Nashville. His primary collaborations include Vanderbilt Specialty Pharmacy, the Department of Physical Medicine and Rehabilitation, and the Center for Research and Innovation in Systems Safety, and he won our department's 2020 Linda Stewart Applied Analysis Report Award for his project on healthcare costs and utilization. His interests outside of work include cooking, hiking, camping, listening to heavy metal, and having fun with his daughters.
DeClercq has published more than 25 peer-reviewed papers to date, often in collaborations with professor Leena Choi and senior associate Dan Ayers. Recent articles about and examples of DeClercq's work include:
- Specialty pharmacists help reduce MS relapse risk (VUMC News, 2022)
- Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis (Journal of Managed Care & Specialty Pharmacy, 2024)
- Adherence and discontinuation of prescription cannabidiol for the management of seizure disorders at an integrated care center (Epilepsy Research, 2024)
- Does interaction occur between risk factors for revision total knee arthroplasty? (Archives of Orthopaedic and Trauma Surgery, 2023)
- Incidence and clinical risk factors of post-operative complications following primary total hip arthroplasty: A 10-year population-based cohort study (Journal of Clinical Medicine, 2023)
As a member of the ACTIV-4 Host Tissue team, he also co-authored the widely read 2023 JAMA report on angiotensin-based treatments among COVID-19 patients.
